Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000
Company may now initiate Phase 2b trial for treatment of demoralization syndrome in patients with cancerNEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health conditions related to life-altering diseases, today announces that the Company has received a Safe to Proceed notification from the U.S. Food and Drug Administration (FDA) regarding its Invest
Source: yahoo.com
